EAGLE, Idaho, June 01, 2023 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced members of the management team will participate in two upcoming June investor conferences.
Wednesday, June 7, 2023 -- William Blair 43rd Annual Growth Stock Conference: The presentation is scheduled for 8:00 a.m. Eastern Time.
Tuesday, June 13, 2023 -- Oppenheimer 23rd Annual Consumer Growth & E-Commerce Virtual Conference: The fireside chat is scheduled for 2:15 p.m. Eastern Time.
The conference presentation and fireside chat will be webcasted and can be accessed live or archived over the Internet hosted at the “Investors” section of the Company's website at www.PetIQ.com.
About PetIQ
PetIQ is a leading pet medication and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable veterinary products and services. The Company engages with customers through more than 60,000 points of distribution across retail and e-commerce channels with its branded and distributed medications as well as health and wellness items, which are further supported by its world-class medications manufacturing facility in Omaha, Nebraska and health and wellness manufacturing facility in Springville, Utah. The Company’s national service platform operates in over 2,600 retail partner locations in 41 states providing cost effective and convenient veterinary wellness services. PetIQ believes that pets are an important part of the family and deserve the best products and care we can give them.
Investors: This email address is being protected from spambots. You need JavaScript enabled to view it. or 208.513.1513
Media: This email address is being protected from spambots. You need JavaScript enabled to view it. or 407.929.6727
Last Trade: | US$21.78 |
Daily Change: | 0.08 0.37 |
Daily Volume: | 435,316 |
Market Cap: | US$642.950M |
May 08, 2024 March 14, 2024 February 28, 2024 December 20, 2023 November 07, 2023 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB